U.S. markets close in 3 hours 41 minutes
  • S&P 500

    4,232.36
    +30.74 (+0.73%)
     
  • Dow 30

    34,703.98
    +155.45 (+0.45%)
     
  • Nasdaq

    13,794.68
    +161.83 (+1.19%)
     
  • Russell 2000

    2,263.17
    +21.75 (+0.97%)
     
  • Crude Oil

    65.03
    +0.32 (+0.49%)
     
  • Gold

    1,833.10
    +17.40 (+0.96%)
     
  • Silver

    27.46
    -0.02 (-0.06%)
     
  • EUR/USD

    1.2161
    +0.0092 (+0.77%)
     
  • 10-Yr Bond

    1.5660
    +0.0050 (+0.32%)
     
  • GBP/USD

    1.3993
    +0.0100 (+0.72%)
     
  • USD/JPY

    108.5740
    -0.5110 (-0.47%)
     
  • BTC-USD

    57,991.52
    +886.59 (+1.55%)
     
  • CMC Crypto 200

    1,504.65
    +68.86 (+4.80%)
     
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • Nikkei 225

    29,357.82
    +26.45 (+0.09%)
     

Perrigo: Q4 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Perrigo (NYSE:PRGO) rose 0.6% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share fell 12.26% over the past year to $0.93, which missed the estimate of $1.00.

Revenue of $1,290,000,000 declined by 2.49% from the same period last year, which missed the estimate of $1,320,000,000.

Guidance

Perrigo sees FY21 adjusted EPS of $2.50-$2.70.

Details Of The Call

Date: Mar 01, 2021

View more earnings on PRGO

Time: 08:00 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1059/40062

Price Action

52-week high: $62.25

Company's 52-week low was at $38.20

Price action over last quarter: down 10.73%

Company Profile

Perrigo is the leading provider of over-the-counter generic drugs with over 100 global locations. The company was formed in 1887 as a packager of home remedies and has grown with the migration of prescriptions switching to OTC and later with strategic acquisitions. The company has a portfolio of more than 3,000 product formulations and 14,000 stock-keeping units. Most of its manufacturing and customer base reside in North America. With the most recent management change, the company announced a narrower focus on consumer wellness in conjunction with the divestiture of animal health, acquisition of Ranir Global Holdings, and plans to sell or spin off the prescription business.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.